2004 Fiscal Year Final Research Report Summary
Investigation on the genome information which is useful for the prediction of clinical effect and adverse effect of new antidepressant, paroxetine
| Project/Area Number |
15591219
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Psychiatric science
|
|---|
| Research Institution | Dokkyo University School of Medicine |
|---|
Principal Investigator |
SHIMODA Kazutaka Dokkyo University School of Medicine, Department of Psychiatry, Associate Professor, 医学部, 助教授 (30196555)
|
|---|
| Project Period (FY) |
2003 – 2004
|
| Keywords | antidepressants / metabolism / interindividual difference / genetic polymorphism / cytochrome P450 |
|---|
| Research Abstract |
In this research project, individualized pharmacotherapy utilizing the genome information for patients with depression has been focused. In 2003, the effect of genetic polymorphism of serotonin transporter (5HTTLPR) on the clinical response and side effect of paroxetine(PAX), which is representative selective serotonin reuptake inhibitor, was investigated. No significant effect of genetic polymorphism (L/S polymorphism) of serotonin transporter on the clinical effect of PAX was observed. In the subjects with side effects of PAX, the frequency of L/S genotype was approximately 40%, while the frequency of L/S genotype in the subjects without any side effects of PAX was 17%. In 2004, the relationship between the side effects of PAX and genetic polymorphism of 5HTTLPR of variable number of tandem repeat(VNTR) or serotonin 2A receptor polymorphism (-1438 A/G polymorphism) was investigated. Although serotonin 2A receptor polymorphism had no significant effect on the emergence of the gastrointestinal side effect of PAX, the subject, all of the subjects with gastrointestinal side effect of PAX had 10/10 genotype of VNTR polymorphism.
|
Research Products
(8 results)
